Trials / Enrolling By Invitation
Enrolling By InvitationNCT06544109
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Venetoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail
- Status
- Enrolling By Invitation
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | venetoclax | patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-08-01
- Completion
- 2028-08-01
- First posted
- 2024-08-09
- Last updated
- 2024-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06544109. Inclusion in this directory is not an endorsement.